tbuckley/cabot-search huggingface dataset:
Low-grade gliomas in older patients.
Authors: Adewale Alade Fawole, Lizbeth Robles Irizarry, Neda Hashemi-Sadraei, Mital Patel, Manmeet Singh Ahluwalia
Journal: Journal of Clinical Oncology (2012)

2093 Background: Low grade gliomas account for 10-20% of all primary brain tumors. The outcomes of older patients with low-grade glioma (LGG) are not well known. Methods: After obtaining IRB approval, the Cleveland Clinic Brain Tumor and Neuro-Oncology Center’s database was used to identify older patients defined as those &gt;55 years of age with histologically confirmed grade 2 glioma at the time of diagnosis. Multivariable analysis was conducted with use of a Cox proportional hazards model and a stepwise selection algorithm that used p&lt;.10 as the criteria for entry and p&lt;0.05 as retention in the model to identify independent predictors of survival. Results: Chart records of 61 patients diagnosed between 1991 and 2010 were included for final analysis. In contrast to patients ≤55 years, older patients are more likely to be male (p=.06), have poorer performance status at presentation (p&lt;.0001), more comorbid conditions (p&lt;.0001), present with more neurologic symptoms (p&lt;.0001), have a prior history of cancer (p&lt;.0001). They are more likely to have astrocytic histology (p=.008) and present with multifocal tumors more frequently (p=.001). Older patients received radiation (RT) upfront more frequently (p=.07) and undergo gross total resection less frequently (p=.003). Median Progression free survival (PFS) and median overall survival (OS) was 1.9 and 4.3 years, respectively in these patients. On univariate analysis, patients with poor performance status have worse PFS (p=.01) and OS (p=.003). Patients with memory impairment have worse PFS (p=.009) and OS (p=.0001). Patients treated with adjuvant chemotherapy had better OS (p=.01). Tumor related characteristics associated with poor survival included, "pure" or mixed astrocytoma histology (OS, p=.06), multifocal tumors (OS, p=.08), left-sided tumors (p=.07). In multivariable analysis, performance status was the only independent predictor of either PFS or OS. Conclusions: Older patients with low grade gliomas have less favorable outcomes as compared to younger patients. They have more comorbid conditions and symptoms at presentation. Use of chemotherapy in this patient group was associated with improved survival. Performance status was the only independent predictor of either PFS or OS.
Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS)
Authors: Birgit M Reipert, Bagirath Gangadharan, Christoph J Hofbauer, Fritz Scheiflinger, Joel Bowen, Elizabeth Donnachie, Karen Fijvandraat, Ralph A. Gruppo, Jenny Klintman, Christoph Male, Catherine E. McGuinn, Shannon L. Meeks, Michael Recht, M V Ragni, Hassan M Yaish, Elena Santagostino, Deborah L Brown
Journal: Blood (2016)
The Paternal Epigenome Makes Its Mark
Authors: Jennifer Abbasi
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Mimics on Brain Magnetic Resonance Imaging in Myotonic Dystrophy Type I
Authors: Daniele Konzen, Carolina Fischinger Moura de Souza, Jonas Alex Morales Saute
Journal: JAMA Neurology (2017)

A woman in her 50s was referred to genetic consultation owing to mitochondrial myopathy or cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy suspicion based on brain magnetic resonance imaging and was diagnosed as having myotonic dystrophy type 1.
Validation of Genomic-Based Risk Models in Myelofibrosis and Proposal of Age-Independent Disease-Specific Models
Authors: Andrew Kuykendall, Chetasi Talati, Najla Al Ali, Eric Padron, David Sallman, Jinming Song, Ling Zhang, Jeffrey E. Lancet, Kendra L. Sweet, Alan F. List, Kenneth S. Zuckerman, Rami S. Komrokji
Journal: Blood (2016)
Sickness Absence and Disability Pension After Breast Cancer Diagnosis: A 5-Year Nationwide Cohort Study
Authors: Pia Kvillemo, Ellenor Mittendorfer-Rutz, Richard Bränström, Kerstin Nilsson, Kristina Alexanderson
Journal: Journal of Clinical Oncology (2017)

Purpose To explore future diagnosis-specific sickness absence and disability pension among women with breast cancer compared with women without breast cancer. Also, to examine associations with disease-related and sociodemographic factors among those with breast cancer. Methods Longitudinal register data on 3,547 women living in Sweden (age 20 to 65 years) who were first diagnosed with breast cancer in 2005, and a matched comparison cohort (n = 14,188), were analyzed for the annual prevalence of diagnosis-specific sickness absence and disability pension over 5 years. Logistic regressions were used to explore associations of disease-related and sociodemographic factors with future sickness absence and disability pension among women with breast cancer. Results Immediately after being diagnosed with breast cancer, the proportion of women with sickness absence was high but decreased continuously from the 1st through 5th year after diagnosis (71%, 40%, 30%, 22%, and 19%, respectively). In comparison, the range for women without breast cancer was 17% to 11%, respectively. The higher prevalence of sickness absence after breast cancer was mainly a result of breast cancer diagnosis, not a mental diagnosis, or other somatic diagnoses. Advanced cancer at diagnosis, > 90 days sickness absence before diagnosis, low education, and being born outside Sweden were associated with higher odds ratios for sickness absence and disability pension (odds ratio range, 1.40 to 6.45). Conclusion The level of sickness absence increased substantially in women with breast cancer during the first year after diagnosis and approached the level of breast cancer-free women in the following years; however, even in the first year, most women were not on sickness absence for a substantial time, and even in high-risk groups, many were not on sickness absence or disability pension in the following years. Information about relatively low future sickness absence and disability pension levels can be used by patients when planning their work, by health care professionals, and by social insurance officers. Employers and Occupational Health Services need this information to adequately handle workplace adjustments.
US RUGBY-7S: THE AMERICAN EXPERIENCE WITH A GROWING AMATEUR COLLISION SPORT
Authors: Victor Lopez, Richard Ma, Meryle Weinstein, Patria Hume, Robert Cantu, Christian Victoria, Erica Marcano, Allen Answorth
Journal: British Journal of Sports Medicine (2017)

Background There are limited data on Rugby-7s, an emerging sport in the United States (US), which debuted in the 2016 Olympics. Objective To report incidence and causes for US Rugby-7s. We hypothesized that match injuries would be frequent and patterns of injuries would be similar in the US population to international cohorts. Design Prospective descriptive epidemiology study. Setting The study encompassed U19 to elite players in USA Rugby tournaments (2010–2013). Participants A total of 13,644 US players (Men=9,768; Women=3,876; age: 13–49 years) were included over 28 tournaments (37 days) of 2,688 matches (Men=1,886; Women=802) in 1,137 sides/teams (Men=814; Women=323). Assessment of Risk Factors Intrinsic and extrinsic risk factors in Rugby-7s match injuries. Main measurement outcome Injury incidence (per 1000 player-hour (ph)) and mechanism captured using the Rugby Injury Survey &amp; Evaluation ( RISE ) Report methodology. Time-loss injuries were defined as players who did not return to play the day of their injury. Injury severity was defined as days absent before return to training/competition (including post tournament). Results Overall incidence of time-loss injuries was 50.6/1000 ph. Time-loss injuries were highest among sub-elite level players (69.5/1000 ph) ( P &lt;0.001). Fifty percent of all injuries occurred in 20–25 year olds which was consistent with the age distribution of the participants. The average injury severity was 44 days (CI 37.7–49.4) for the 97% of players with follow-up data. Most tournament match injuries were new acute injuries (95%), occurred during tackling (68%), were ligament sprains (35%), and in the lower extremity (52%). Head/face (22.6%) and upper extremity (24.7%) injuries were also frequent. Conclusions Compared to international elite cohorts, the US amateur population had lower overall injury incidence, however, they had a higher frequency of upper extremity and head/face injuries. Injury prevention protocols in the US should focus on tackling techniques, which may reduce incidence of tournament match injuries.
Survival outcomes for patients requiring re-liver transplantation
Authors: A Qasim, B Zaman, B Blake, T Tajuddin, J Geoghegan, D Maguire, O Traynor, J Hegarty, A McCormick
Journal: Endoscopy (2005)

Introduction: Re-liver transplantation (re-LT) is required in substantial number of patients due to disease recurrence or transplant complications.
Abstract 18929: The Role of Clec9a in Atherosclerosis Development
Authors: Yacine Haddad, Charlotte Lahoutte, Marc Clément, Ludivine Laurans, Sarvenaz Metghalchi, Xavier Loyer, Marie Vandestienne, Julien Wain-Hobson, Stephane Potteaux, Hafid Ait-Oufella, Bruno Esposito, David Sancho, Alain Tedgui, Ziad Mallat, Soraya Taleb
Journal: Circulation (2016)

Necrotic core formation during the development of atherosclerosis is associated with a chronic inflammatory response and promotes accelerated plaque development and instability. We hypothesized tha...
Sensitive and non-invasive assessment of hepatocellular iron using a novel room-temperature susceptometer
Authors: Johannes Mueller, Hanna Raisi, Vanessa Rausch, Teresa Peccerella, David Simons, Christian Herbert Ziener, Heinz-Peter Schlemmer, Helmut Karl Seitz, Nina Waldburger, Thomas Longerich, Beate Katharina Straub, Sebastian Mueller
Journal: Journal of Hepatology (2017)
Handgun Acquisitions in California After Two Mass Shootings
Authors: David M. Studdert, Yifan Zhang, Jonathan A. Rodden, Rob J. Hyndman, Garen J. Wintemute
Journal: Annals of Internal Medicine (2017)

Mass shootings are common in the United States. They are the most visible form of firearm violence. Their effect on personal decisions to purchase firearms is not well-understood.To determine changes in handgun acquisition patterns after the mass shootings in Newtown, Connecticut, in 2012 and San Bernardino, California, in 2015.Time-series analysis using seasonal autoregressive integrated moving-average (SARIMA) models.California.Adults who acquired handguns between 2007 and 2016.Excess handgun acquisitions (defined as the difference between actual and expected acquisitions) in the 6-week and 12-week periods after each shooting, overall and within subgroups of acquirers.In the 6 weeks after the Newtown and San Bernardino shootings, there were 25 705 (95% prediction interval, 17 411 to 32 788) and 27 413 (prediction interval, 15 188 to 37 734) excess acquisitions, respectively, representing increases of 53% (95% CI, 30% to 80%) and 41% (CI, 19% to 68%) over expected volume. Large increases in acquisitions occurred among white and Hispanic persons, but not among black persons, and among persons with no record of having previously acquired a handgun. After the San Bernardino shootings, acquisition rates increased by 85% among residents of that city and adjacent neighborhoods, compared with 35% elsewhere in California.The data relate to handguns in 1 state. The statistical analysis cannot establish causality.Large increases in handgun acquisitions occurred after these 2 mass shootings. The spikes were short-lived and accounted for less than 10% of annual handgun acquisitions statewide. Further research should examine whether repeated shocks of this kind lead to substantial increases in the prevalence of firearm ownership.None.
Multiple uses for a clinical research database
Authors: A. O. Greco, C. M. Licavoli, L. A. White, J. R. Eckardt, K. O. Easley, N. N. Sjak-Shie
Journal: Journal of Clinical Oncology (2007)

17037 Background: In Sept 2000, the research staff at The Center for Cancer Care and Research (TCCCR) developed an excel data base to track new consults referred to the practice. It is used to identify pts for participation in Cooperative Group Clinical Trials and to identify gaps in the active protocol list. Several additional uses for the data base have evolved. Methods: Medical records provided by referring physicians for each new consult are evaluated by a Research Coordinator. Information including the pt's name, date of visit, physician, referring physician, diagnosis, protocol for which the pt is evaluated, and eligibility information is entered in the data base. Results: The data base provides a method by which we can follow pts through the protocol selection and informed consent process. Early on, the data base identified a site need for trials in metastatic breast cancer prompting us to search other sources such as the CTSU and industry. Additionally, the percentage of new consults actually enrolled on a clinical trial can be determined as well as tracking eligibility/ineligibility trends. The Pharmaceutical Research Dept can use the information to complete feasibility studies prior to participating in industry trials. The data base can be used to evaluate trends in referral patterns and has helped identify referring physicians who support our research efforts. In 2006, TCCCR had a protocol available for 45% of new consults with a cancer dx. Of those pts, 16% enrolled on a Cooperative Group Clinical Trial. According to published evaluations, 16% is well above the national average of pts who participate in oncology clinical trials. It is our assessment that TCCCR's success is due in part to the data base. Conclusions: It is well known that in order to improve treatment outcomes and diminish treatment toxicity, oncology practices and pts must participate in clinical research. It is also well known that the numbers of pts who participate in oncology clinical trials is dismal. This data base has become a valuable tool providing a method to identify and evaluate some of the reasons why pts do not enroll in clinical trials and given our practice guidance to increase pt participation. Our next goal is to evaluate the differences between the rural and urban population at TCCCR's two sites to identify additional trends in clinical trial participation. No significant financial relationships to disclose.
Annals Story Slam - Why Us? Why Not Us?
Authors: Rebecca Hoffman
Journal: Annals of Internal Medicine (2017)

Web Exclusives2 May 2017Annals Story Slam - Why Us? Why Not Us?FREERebecca Hoffman, MDRebecca Hoffman, MDFrom University of Pennsylvania, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0042 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Why Us? Why Not Us? "Why Us? Why Not Us?," by Dr. Rebecca Hoffman (Duration 7:10)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From University of Pennsylvania, Philadelphia, Pennsylvania.Current Author Address: Rebecca Hoffman, MD, University of Pennsylvania, Philadelphia, PA; e-mail, Rebecca.[email protected]upenn.edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 2 May 2017Volume 166, Issue 9Page: SS1 ePublished: 2 May 2017 Issue Published: 2 May 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Limitations of Study on Symptom Checkers—Reply
Authors: Ateev Mehrotra, Hannah L. Semigran, David M. Levine, Shantanu Nundy
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Efficacy of yttrium-90 (Y90) radioembolization in patients with chemorefractory colorectal cancer (CRC) liver metastasis: Results of Bologna study.
Authors: Carmine Pinto, Cristina Mosconi, Bruna Angelelli, Vita Mutri, Emanuela Giampalma, Alberta Cappelli, Fabio Monari, Cinzia Pettinato, Maurizio Levorato, Stefania Giaquinta, Francesca Di Fabio, Fabiola Lorena Rojas Llimpe, Daniela Adua, Barbara Melotti, Claudia Degli Esposti, Pierluigi Guidalotti, Stefano Fanti, Renzo Mazzarotto, Rita Golfieri
Journal: Journal of Clinical Oncology (2014)

e14547 Background: Y90 radioembolisation is a promising treatment for chemorefractory CRC liver metastasis patients (pts). This pilot study investigated in a single institution the safety/efficacy of the Y90 therapy. Methods: We enrolled consecutive pts referred to S.Orsola-Malpighi Hospital, Bologna, whose CRC liver metastasis had progressed to ≥2 CT lines was enrolled. Eligible pts had: adequate hepatic function, absence of mayor hepatic vascular anomalies, only liver metastasis or liver metastasis with limited extra-hepatic disease. Safety was assessed according to CTC-NCI 3.0 at 1 week and monthly thereafter for 6 months post-therapy. Efficacy was assessed by CT at 1, 3 and 6 months. PFS/OS analysis was performed using the Kaplan-Meier estimation. Predictive factors were tested using Cox analysis. Results: Between January 2006-April 2013, 56 pts were enrolled and underwent Y90 therapy. Pt characteristics were: 43(76.8%)M, 13(23.2%)F; median age 64(42-82) y; ECOG PS-0 49(87.5%), PS-1 7(12.5%); previous 2 CT lines 25(44.6%), >2 CT lines 31(55.4%); only liver metastasis 45(80%), liver plus extra-hepatic metastasis 11(20%); n.of liver metastasis ≤5 23(41%), >5 33(59%); bilobar liver metastasis 32 pts (56.1%); median diameter liver metastasis 57 mm (1.1-13.0); synchronous liver metastasis 33(59%) Median activity per treatment session was 1.66 GBq (0.50-2.31); n.of treatments was 1 in 51(91.1%), 2 in 5(8.9%). Therapies post-Y90 were: no-treatment 45(80%), 7(12.5%) systemic CT, 2(3.6%) hepatic surgery, 1(1.8%) other surgery, 1(1.8%) percutaneous ablation. The main toxicity was G3 in 2(3.6%) pts (1 gastric ulcer, 1 radiation gastritis). Hepatic ORR and DCR at 1 months and confirmed at 3 months were 23.2% (12/56) and 35.7% (20/56), respectively Median PFS and OS from the first Y90 was 4 months (95%, CI 3-5) and 8 months (95%CI, 5-11), respectively. No predictive parameters were identified including CEA, n./diameter of hepatic lesions, extra-hepatic disease, number/regimen of CT lines. Conclusions: These results show that introducing Y90 in the treatment strategy of selected CRC pts has a favourable safety profile and could have a positive impact on survival
Ibrutinib Abrogates TREM-1 Mediated Neutrophil Activation
Authors: Nicole Stadler, Astrid Hasibeder, Pamela Aranda Lopez, Alexander Desuki, Oliver Kriege, Alexander N.R. Weber, Christian Michel, Daniel Teschner, Georg Hess, Matthias Theobald, Markus Radsak
Journal: Blood (2016)
Separating Families at the Border — Consequences for Children’s Health and Well-Being
Authors: Michael J. MacKenzie, Emily Bosk, Charles H. Zeanah
Journal: New England Journal of Medicine (2017)

Though he no longer claims the policy would aim to deter other migrant families, Secretary of Homeland Security John Kelly has left open the possibility of separating children from their parents at the border — threatening children's growth, health, and well-being.
The validity of cause of death coding within the Surveillance, Epidemiology, and End Results (SEER) Registry
Authors: C. Hu, Y. Xing, J. N. Cormier, G. J. Chang
Journal: Journal of Clinical Oncology (2009)

6544 Background: Disease-specific survival (DSS) analysis within large cancer registries is more informative than other methods of survival analysis but requires accurate information regarding the cause of death (COD). The purpose of this study was to evaluate the validity of the COD code for patients diagnosed with colon cancer and the extent to which it varies with regard to age, sex, and race within SEER. Methods: Patients with colon adenocarcinoma were identified from SEER (ver. 2008) from 1988 to 1998 to have at least 7 years of follow-up. Relative survival (RS) was calculated matching for age, sex, and the year of diagnosis using U.S. life-tables. Colon cancer cause of death was then assigned using SEER COD recode for colon and rectal death (21040–50). The number of observed and expected deaths by year was calculated to estimate deaths attributable to colon cancer. The ratio of this number to the recorded cause of death was defined as the validity of the COD code in SEER. Results: 86,641 patients were identified. Relative survival declined during the first 7 years of observation but then leveled indicating a minimum number of deaths subsequently attributable to colon cancer. At year 7 the observed number of deaths for the SEER cohort was 49,104; the expected number of deaths using life tables was 17,173. The difference (31,931) is theoretically attributable to colon cancer. Within the SEER cohort, 30,227 deaths were coded colorectal cancer deaths, an estimated validity of 94.6%. Stratified results demonstrated validity was sensitive to race but not age or gender (table). Conclusions: Cause of death coding for colon cancer in SEER is highly valid, suggesting that the use of DSS for colon cancer is appropriate. [Table: see text] No significant financial relationships to disclose.